RJ Bio-Tech Key Ratios
BSE: 536456
₹3.43
₹0.02
(0.59%)
As on 01-Apr-2024IST
Market cap
₹3 Cr
Revenue (TTM)
₹14 Cr
P/E Ratio
--
P/B Ratio
--
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -42.85 | 91.58 | 13.55 | 11.17 | -2.44 |
| EBIT | -232.19 | -237.90 | 13.26 | 29.38 | 16.09 |
| Net Profit | -406.49 | -103.68 | 55.59 | 18.14 | 11.59 |
| EPS | -406.49 | -103.68 | 55.59 | 18.14 | 11.59 |
| Book Value | -- | -- | -22.24 | -162.99 | -239.32 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-22 | Mar-21 | Mar-20 |
| EBIT-Margin
| -32.76 | -53.05 | 8.98 | -80.46 | -26.79 |
| Net Margin
| -29.32 | -100.55 | -27.79 | -- | -30.85 |
| Return on equity
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Return on Capital
| -79.36 | -64.49 | 0.00 | -218.35 | -19.75 |
| Return on Assets
| -73.33 | -61.39 | -104.09 | -100.28 | -15.63 |
| Debt to Equity (x)
| -- | -- | -1.01 | -0.98 | -1.57 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
--
|
-218.35
|
-19.75
|
-32.76
|
-51.57
|
|
Peer Median
|
11.30
|
13.51
|
8.19
|
12.26
|
14.49
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
8.83
|
13.05
|
6.87
|
14.73
|
20.36
|
ROA
-104.09
Lower than Peers by 109.59
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-104.09
|
-100.28
|
-15.63
|
-36.69
|
-50.28
|
|
Peer Median
|
5.50
|
7.39
|
3.43
|
6.31
|
5.74
|
EBIT Margin
8.98
Higher than Peers by 0.68
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
8.98
|
-80.46
|
-26.79
|
-74.43
|
-92.54
|
|
Peer Median
|
8.30
|
10.08
|
10.16
|
8.43
|
8.83
|
Net Margin
-27.79
Lower than Peers by 31.06
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-27.79
|
-99.28
|
-30.85
|
-112.49
|
-231.08
|
|
Peer Median
|
3.27
|
5.95
|
4.44
|
3.51
|
5.57
|
Cash Profit Margin
-28.65
Lower than Peers by 28.65
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-28.65
|
-98.70
|
-30.33
|
-112.50
|
-231.55
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-12.02
Lower than Peers by 58.66
Year on year growth in net sales
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-12.02
|
18.24
|
32.06
|
14.35
|
-43.75
|
|
Peer Median
|
46.63
|
8.63
|
7.31
|
17.67
|
9.31
|
EBIT Growth
109.82
Lower than Peers by 3.49
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
109.82
|
-255.10
|
52.46
|
8.03
|
28.64
|
|
Peer Median
|
113.31
|
28.04
|
27.37
|
24.51
|
15.98
|
Net Profit Growth
74.18
Lower than Peers by 34.00
Year on year growth in profit after tax
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
74.18
|
-277.31
|
63.95
|
44.47
|
-38.29
|
|
Peer Median
|
108.18
|
24.65
|
59.60
|
33.62
|
45.79
|
EPS Growth
74.18
--
Year on year growth in earnings per share
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
74.18
|
-277.31
|
63.95
|
44.47
|
-38.29
|
|
Peer Median
|
--
|
20.55
|
62.71
|
-15.80
|
18.75
|
Book Value Growth
-22.24
--
Year on year growth in book value per share
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-22.24
|
-54.82
|
-18.88
|
-105.57
|
-213.49
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-1.01
Lower than Peers by 1.32
Total debt / Net worth
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-1.01
|
-0.98
|
-1.57
|
-1.84
|
-3.41
|
|
Peer Median
|
0.31
|
0.26
|
0.26
|
0.57
|
0.38
|
Short term debt to equity ratio
-0.93
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-0.93
|
-0.88
|
-1.42
|
-1.66
|
-3.20
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.01
Lower than Peers by 1.97
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
0.01
|
0.09
|
0.49
|
0.56
|
0.81
|
|
Peer Median
|
1.97
|
1.70
|
1.75
|
2.45
|
1.67
|
Quick Ratio
0.01
Lower than Peers by 1.95
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
0.01
|
0.06
|
0.17
|
0.25
|
0.46
|
|
Peer Median
|
1.95
|
1.62
|
1.50
|
2.54
|
2.15
|
Interest Coverage
0.30
Lower than Peers by 3.26
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
0.30
|
-6,943.08
|
-4.30
|
-1.79
|
-4.34
|
|
Peer Median
|
3.57
|
5.82
|
3.55
|
5.39
|
3.04
|
Operating Efficiency
Debtors to sales
1.99
Lower than Peers by 30.88
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
1.99
|
5.25
|
55.16
|
99.05
|
188.07
|
|
Peer Median
|
32.87
|
32.98
|
34.40
|
22.66
|
30.22
|
Asset Turnover
3.57
Higher than Peers by 2.43
Sales / Average Total Assets
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
3.57
|
1.01
|
0.50
|
0.32
|
0.22
|
|
Peer Median
|
1.15
|
1.07
|
0.83
|
2.37
|
2.46
|
Receivable days
14.52
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
14.52
|
94.72
|
237.13
|
480.92
|
731.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
--
|
179.09
|
380.60
|
491.48
|
761.77
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
18.67
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
18.67
|
40.89
|
161.00
|
173.18
|
122.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
-4.15
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-4.15
|
232.92
|
456.73
|
799.22
|
1,370.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
24.00
|
29.96
|
16.10
|
15.00
|
13.95
|
Price / Book Value
-0.10
Lower than Peers by 1.66
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
-0.10
|
-0.15
|
-0.46
|
-0.82
|
-2.13
|
|
Peer Median
|
1.56
|
2.12
|
1.67
|
1.20
|
1.75
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
0.02
|
--
|
--
|
--
|
EV/EBITDA
27.91
Higher than Peers by 11.58
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
27.91
|
-3.69
|
-16.05
|
-8.22
|
-7.68
|
|
Peer Median
|
16.34
|
13.54
|
9.91
|
12.72
|
11.69
|
Market Cap
5
Lower than Peers by 204
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
Mar-22
|
Mar-21
|
Mar-20
|
Mar-19
|
Mar-18
|
|---|---|---|---|---|---|
|
RJ Bio-Tech
|
5
|
6
|
12
|
18
|
23
|
|
Peer Median
|
209
|
392
|
252
|
128
|
291
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
